

Claims

1. A pharmaceutical formulation comprising fulvestrant in a ricinoleate vehicle, a pharmaceutically acceptable non-aqueous ester solvent, and a pharmaceutically acceptable alcohol wherein the formulation is adapted for intramuscular administration and attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.
 2. A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation which is capable after injection of attaining a therapeutically significant blood plasma fulvestrant concentration for at least 2 weeks.
 3. A pharmaceutical formulation as claimed in claim 1 or 2 wherein the blood plasma fulvestrant concentration attained is at least 2.5ngml^{-1} for at least 2 weeks..
 4. A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 30% or less weight of a pharmaceutically-acceptable alcohol per volume of formulation, at least 1% weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml^{-1} of fulvestrant.
 5. A pharmaceutical formulation as claimed in claim 1 to 4 which contains 25% w/v or less of a pharmaceutically-acceptable alcohol.
- 25
6. A pharmaceutical formulation as claimed in claim 5 which contains 20% w/v or less of a pharmaceutically-acceptable alcohol.
 7. A pharmaceutical formulation as claimed in claim 5 which contains 15-25% w/v of a pharmaceutically acceptable alcohol.
- 30
8. A pharmaceutical formulation as claimed in claim 5 which contains 17-23% w/v of a pharmaceutically acceptable alcohol.

9. A pharmaceutical formulation as claimed in any claim from 1 to 8 which contains 60% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.
10. A pharmaceutical formulation as claimed in claim 9 which contains 50% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent .
5
11. A pharmaceutical formulation as claimed in claim 9 which contains 45% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.
- 10 12. A pharmaceutical formulation as claimed in claim 9 which contains 40% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.
13. A pharmaceutical formulation as claimed in claim 9 which contains 35% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.
15
14. A pharmaceutical formulation as claimed in claim 9 which contains 30% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.
15. A pharmaceutical formulation as claimed in claim 9 which contains 25% w/v or less of a pharmaceutically-acceptable non-aqueous ester solvent.
20
- 16 A pharmaceutical formulation as claimed in claim 9 which contains 10-25% w/v of a pharmaceutically acceptable non-aqueous ester solvent.
- 25 17 A pharmaceutical formulation as claimed in claim 9 which contains 12-18% w/v of a pharmaceutically acceptable non-aqueous ester solvent.
- 18 A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 15-25% weight of a pharmaceutically-acceptable alcohol per volume of
30 formulation, 10-25 % weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml^{-1} of fulvestrant.

- 19 A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 17-23% weight of a pharmaceutically-acceptable alcohol per volume of formulation, 12-18 % weight of a pharmaceutically-acceptable non-aqueous ester solvent miscible in a ricinoleate vehicle per volume of formulation and a sufficient amount of a 5 ricinoleate vehicle so as to prepare a formulation of at least 45mgml^{-1} of fulvestrant.
20. A pharmaceutical formulation as claimed in any claim from 1 to 19 wherein the pharmaceutically-acceptable alcohol is a mixture of ethanol and benzyl alcohol.
- 10 21. A pharmaceutical formulation as claimed in any claim from 1 to 20 wherein the pharmaceutically-acceptable non-aqueous ester solvent is selected from benzyl benzoate, ethyl oleate, isopropyl myristate, isopropyl palmitate or a mixture of any thereof.
22. A pharmaceutical formulation as claimed in any claim from 1 to 21 wherein the 15 pharmaceutically-acceptable non-aqueous ester solvent is benzyl benzoate.
- 23 A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 15-25% weight of a pharmaceutically-acceptable alcohol per volume of formulation, 10-25 % weight of benzyl benzoate in a ricinoleate vehicle per volume of 20 formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml^{-1} of fulvestrant.
- 24 A pharmaceutical formulation adapted for intra-muscular injection comprising fulvestrant, 17-23% weight of a pharmaceutically-acceptable alcohol per volume of 25 formulation, 12-18 % weight of benzylbenzoate in a ricinoleate vehicle per volume of formulation and a sufficient amount of a ricinoleate vehicle so as to prepare a formulation of at least 45mgml^{-1} of fulvestrant.
- 25 A pharmaceutical formulation according to claim 23 or 24 wherein the 30 pharmaceutically-acceptable alcohol is a mixture of ethanol and benzyl alcohol.
- 26 A pharmaceutical formulation according to claim 25 wherein the ethanol and benzyl alcohol are present at about equal % weight per volume of formulation.

27. A pharmaceutical formulation as claimed in any claim from 1 to 26 wherein the total volume of the formulation is 6ml, or less, and the concentration of fulvestrant is at least 45mgml⁻¹.

5

28. A pharmaceutical formulation as claimed in any claim from 1 to 27 wherein the total amount of fulvestrant in the formulation is 250mg, or more, and the total volume of the formulation is 6ml, or less.

10 29. A pharmaceutical formulation as claimed in claim 28 wherein the total amount of fulvestrant in the formulation is 250mg and the total volume of the formulation is 5 to 5.25ml.

30. A pharmaceutical formulation as claimed in any of claims 1-29 wherein the pharmaceutically-acceptable alcohol is a mixture of 10% weight of ethanol per volume of
15 formulation, 10% weight of benzyl alcohol per volume of formulation, and the formulation contains 15% weight of benzyl benzoate per volume of formulation and the ricinoleate vehicle is castor oil.

31. A pharmaceutical formulation adapted for intramuscular injection, as defined in any
20 claim from 1 to 30, for use in medical therapy.

32. Use of fulvestrant in the preparation of a pharmaceutical formulation, as defined in any claim from 1 to 30, for the treatment of a benign or malignant disease of the breast or reproductive tract.

25

33. A syringe or vial containing a pharmaceutical formulation as defined in claim 30.

30

Z70635WO

Jan2002